Why the study?
Does the extent of LV scar on LGE-CMR predict ventricular arrhythmic events in patients with CAD or non-ischaemic cardiomyopathy?
Does the extent of LV scar on LGE-CMR predict ventricular arrhythmic events in patients with CAD or non-ischaemic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
The extent of late gadolinium enhancement on CMR is strongly associated with ventricular arrhythmias in patients with reduced LVEF, highlighting its potential utility for sudden cardiac death risk stratification.
AIMS: Approaches to the risk stratification for sudden cardiac death (SCD) remain unsatisfactory. Although late gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMR) for SCD risk stratification has been evaluated in several studies, small sample size has limited their clinical validity. We performed this meta-analysis to better gauge the predictive accuracy of LGE-CMR for SCD risk stratification. METHODS AND RESULTS: Electronic databases and published bibliographies were systematically searched to identify studies evaluating the association between the extent of LV scar on LGE-CMR and ventricular arrhythmic events [SCD, resuscitated cardiac arrest, the occurrence of ventricular arrhythmias, or appropriate implantable cardioverter defibrillator (ICD) therapy]. Only studies enrolling patients with CAD or non-ischaemic cardiomyopathy were included. Summary estimates of the relative risk (RR) and likelihood ratios (LRs) were calculated using random effects models. Eleven studies comprising 1105 patients were identified. During a mean/median follow-up of 8.5-41 months 207 patients had ventricular arrhythmic events. Ventricular arrhythmic events were more common in patients with a greater extent of LV scar: RR 4.33 [95% confidence interval (CI) 2.98-6.29], positive LR 1.98 (95% CI 1.66-2.37), and negative LR 0.33 (95% CI 0.24-0.46). CONCLUSION: The extent of LGE on CMR is strongly associated with the occurrence of ventricular arrhythmias in patients with reduced LVEF and may be a valuable risk stratification tool for identifying patients who will benefit from ICD therapy. However, uncertainties regarding clinical application persist and need to be addressed prior to introduction into broad clinical practice.
No takes yet. Share an insight, caveat, or question.
Scott et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: